InvestorsHub Logo
Followers 144
Posts 27648
Boards Moderated 3
Alias Born 02/07/2004

Re: None

Monday, 06/25/2007 4:18:13 AM

Monday, June 25, 2007 4:18:13 AM

Post# of 1367
BreathID completes clinical trial
The company tested its system in the diagnosis of liver disease.
Gali Weinreb 24 Jun 07 18:37
BreathID Ltd. (TASE:BRTI), which was floated a month ago, announced today that it successfully completed a trial on 15 patients with Acute Liver Disease.
The trial, which was conducted at the Hadassah Medical Center assessed the patients using BreatheID's non-invasive device, which diagnoses diseases of the liver and other symptoms by analyzing the composition of the air exhaled from the patients' lungs. The results were then compared with those obtained from the existing procedures for monitoring these patients. It was found that BreathID's device produced similar results to those of the existing testing procedures, without having to wait a day or more for the results.

BreatheID's system is a diagnostic device so the company will be able to begin marketing it to for use in trials at leading medical centers, although its commercial success will depend on the completion of trials on a larger scale. BreathID has already successfully completed trials of its device on patients with Hepatitis C and Non Alcoholic Fatty Liver Disease.

Published by Globes [online], Israel business news - www.globes.co.il - on June 24, 2007

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.